Initium Therapeutics was established to develop innovative antibody-based therapeutics, including pursuing new therapeutic targets in fibrosis, immuno-oncology and hemophilia. Initium was established in June of 2020 as a spin-off of South Korea-based Tiumbio in order to expand its capability to antibody drug development platforms.
Initium says that using its unique antibody development platforms of DNA immunization technology and AbCassette-High express system it generates more diverse antigen-specific B cell repertoire and expedites screening of functional therapeutic antibodies, which mostly recognize very challenging small and complex conformational epitopes of membrane associated protein targets such as GPCRs (G protein coupled receptors), to treat unaddressed rare diseases.
Initium recently announced a strategic collaboration with GenScript ProBio, in which Initium plans to utilize GenScript ProBio’s Berkeley Lights Beacon Platform to expand its antibody drug pipeline.
- BioTryp TherapeuticsBioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on… Read more: BioTryp Therapeutics
- Bastion TherapeuticsBastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class… Read more: Bastion Therapeutics
- HOVANAHOVANA is a digital biology company tackling translational dysfunction as a driver… Read more: HOVANA
- CourageneFounded in 2022, Couragene is a biotechnology company developing first-in-class in vivo… Read more: Couragene
- Function OncologyFunction Oncology is a precision medicine company advancing a CRISPR-powered personalized functional… Read more: Function Oncology
- Mallia TherapeuticsFounded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83… Read more: Mallia Therapeutics